Fig. 1

FBN1 expression level is associated with cisplatin‐resistance in patients with ovarian cancer. (A) Images of cisplatin‐resistant and ‐sensitive organoids derived from ovarian cancer patients with or without 5 μg/L cisplatin treatment for 21 days. (B) Cell viability assay of organoids treated with 5 μg/L cisplatin in different time intervals. The data of 4 pairs of ovarian cancer organoids are shown. Data are presented as mean ±SD of triplicate measurements repeated three times. (C) GSEA analysis was performed using 6 cisplatin‐resistant and 6 ‐sensitive organoids derived from ovarian cancer patients. (D) Immunofluorescence assay was performed to detect the association between FBN1 and cisplatin‐sensitive ovarian cancer organoids. (E) FBN1 mRNA expression in 10 pairs of cisplatin‐resistant and ‐sensitive organoids of ovarian cancer. (F) Representative images of immunohistochemistry staining of FBN1 in 132 cisplatin‐resistant and 129 ‐sensitive ovarian cancer tissues. (G) High‐low expression ratio of FBN1 in cisplatin‐resistant and ‐sensitive ovarian cancer tissues. (H) H‐score of FBN1 in cisplatin‐resistant and ‐sensitive ovarian cancer tissues. (I) qRT‐PCR analysis of FBN1 mRNA expression in 45 pairs of cisplatin‐resistant and ‐sensitive ovarian cancer tissues. (J) Immunofluorescence of FBN1 in cisplatin‐resistant and ‐sensitive ovarian cancer tissues. Red signals, FBN1; blue signals, DAPI. **, P < 0.01. Abbreviations: FBN1, fibrillin‐1; SD, standard deviation; GSEA, Gene Set Enrichment Analysis; qRT‐PCR, quantitative real‐time PCR; DAPI, 2‐(4‐Amidinophenyl)‐6‐indolecarbamidine dihydrochloride